New guideline on treatment of idiopathic pulmonary fibrosis

The Lancet Respiratory Medicine

Volumn 3, Issue 9, 2015, Pages e31-e32

  Spagnolo, Paolo ^a,b   Bonella, Francesco ^c   Maher, Toby M ^d  

^a Medical University Clinic   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c RUHRLANDKLINIK   (Germany)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; BOSENTAN; IMATINIB; MACITENTAN; NINTEDANIB; PIRFENIDONE; PREDNISONE; SILDENAFIL; WARFARIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DECISION MAKING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG QUALITY; FIBROSING ALVEOLITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; IDIOPATHIC PULMONARY FIBROSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PRACTICE GUIDELINES AS TOPIC; PYRIDONES;

EID: 84941137778     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00322-7     Document Type: Letter

References (6)

1. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
3. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977. Idiopathic Pulmonary Fibrosis Clinical Research Network.
4. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015, 192:e3-e19.
5. Karimi-Shah BA, Chowdhury BA Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib. N Engl J Med 2015, 372:1189-1191.
6. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respir Med 2014, 2:933-942.